Phase II trial of Prednimustine. Leo-1031 (NSC-134087) in acute non-lymphocytic leukemia.
18 patients with acute non-lymphocytic leukaemia were treated with Prednimustine, a chlorambucil ester of prednisolone, as a single drug. 5 patients responded with falling blast counts in peripheral blood, but only 1 obtained a complete remission of 3 months' duration. Since the activity of Prednimustine is lower than that of other commonly used drugs in acute non-lymphocytic leukaemia, future studies should concentrate on other aspects, such as treatment of patients with steroid receptor-positive blast cells or other types of leukaemia.
D000328:Adult; D000368:Aged; D002699:Chlorambucil / Q000031:analogs & derivatives*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D004915:Leukemia, Erythroblastic, Acute / Q000188:drug therapy*; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011238:Prednimustine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D002699:Chlorambucil; D011238:Prednimustine